Aquestive Therapeutics, Inc. (AQST) Financial Statements (2024 and earlier)

Company Profile

Business Address 30 TECHNOLOGY DRIVE
WARREN, NJ 07059
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22,43626,882 18,64917,69514,736
Cash and cash equivalents22,43626,882 18,64917,69514,736
Receivables2,1723,5072,1392,1503,4741,823
Inventory, net of allowances, customer advances and progress billings5,9506,9815,7806,7255,0084,629
Inventory5,9506,9815,7806,7255,0084,629
Other undisclosed current assets9,2306,33631,96910,56317,32821,397
Total current assets:39,78843,70639,88838,08743,50542,585
Noncurrent Assets
Operating lease, right-of-use asset5,7785,8845,2112,0942,3142,524
Property, plant and equipment4,6023,8144,0854,2844,5694,496
Intangible assets, net (including goodwill)1,3571,3961,4351,4872538
Intangible assets, net (excluding goodwill)1,3571,3961,4351,4872538
Other noncurrent assets5,4696,4856,4515,8935,8976,886
Total noncurrent assets:17,20617,57917,18213,75812,80513,944
TOTAL ASSETS:56,99461,28557,07051,84556,31056,529
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,95216,94817,91324,09520,12413,364
Taxes payable351267
Employee-related liabilities4,9393,928
Accounts payable10,68912,4409,94611,0728,8878,496
Accrued liabilities4,2634,5087,9677,7337,0424,868
Deferred revenue3,9924,7651,5137741,5991,599
Debt18,36217,19518,70014,2259,7506,563
Other undisclosed current liabilities1,3471,4751,402(2,534)(1,837)2,658
Total current liabilities:38,65340,38339,52836,56029,63624,184
Noncurrent Liabilities
Long-term debt and lease obligation20,80125,19633,44840,01545,32349,390
Long-term debt, excluding current maturities20,80125,19633,44838,67543,82147,680
Liabilities, other than long-term debt40,73640,80438,53619,78115,86915,752
Deferred revenue33,12033,03931,41717,62213,49013,890
Other liabilities2,0062,0592,0342,1592,3791,862
Operating lease, liability5,6105,7065,0851,3401,5021,710
Other undisclosed noncurrent liabilities63,45564,13764,11263,30861,83960,346
Total noncurrent liabilities:124,992130,137136,096123,104123,031125,488
Total liabilities:163,645170,520175,624159,664152,667149,672
Equity
Equity, attributable to parent(106,651)(109,235)(118,554)(107,819)(96,357)(93,143)
Common stock625655545341
Additional paid in capital202,218193,848192,598190,982189,908176,833
Accumulated deficit(308,931)(303,139)(311,207)(298,855)(286,318)(270,017)
Total equity:(106,651)(109,235)(118,554)(107,819)(96,357)(93,143)
TOTAL LIABILITIES AND EQUITY:56,99461,28557,07051,84556,31056,529

Income Statement (P&L) ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Revenues13,24111,13410,68211,46313,26512,270
Cost of revenue
(Cost of Goods and Services Sold)
(6,617)(4,737) (4,625)(5,242)(4,214)
Other undisclosed gross profit   14,081   
Gross profit:6,6246,39724,7636,8388,0238,056
Operating expenses(10,833)(11,002)(35,476)(15,691)(20,785)(17,794)
Operating loss:(4,209)(4,605)(10,713)(8,853)(12,762)(9,738)
Interest and debt expense(1,373)(1,788)(1,650)(1,649)(1,635)(1,618)
Loss from continuing operations before equity method investments, income taxes:(5,582)(6,393)(12,363)(10,502)(14,397)(11,356)
Other undisclosed income (loss) from continuing operations before income taxes7414,46111(2,034)(1,905)(1,864)
Income (loss) from continuing operations before income taxes:(5,508)8,068(12,352)(12,536)(16,302)(13,220)
Income tax expense (benefit)(284)     
Income (loss) from continuing operations:(5,792)8,068(12,352)(12,536)(16,302)(13,220)
Loss before gain (loss) on sale of properties:(12,536)(16,302)(13,220)
Net income (loss) available to common stockholders, diluted:(5,792)8,068(12,352)(12,536)(16,302)(13,220)

Comprehensive Income ($ in thousands)

9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
6/30/2022
Q2
3/31/2022
Q1
Net income (loss):(5,792)8,068(12,352)(12,536)(16,302)(13,220)
Comprehensive income (loss), net of tax, attributable to parent:(5,792)8,068(12,352)(12,536)(16,302)(13,220)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: